Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 20;12(10):1647.
doi: 10.3390/life12101647.

Guanidine Derivatives of Quinazoline-2,4(1 H,3 H)-Dione as NHE-1 Inhibitors and Anti-Inflammatory Agents

Affiliations

Guanidine Derivatives of Quinazoline-2,4(1 H,3 H)-Dione as NHE-1 Inhibitors and Anti-Inflammatory Agents

Alexander Spasov et al. Life (Basel). .

Abstract

Quinazolines are a rich source of bioactive compounds. Previously, we showed NHE-1 inhibitory, anti-inflammatory, antiplatelet, intraocular pressure lowering, and antiglycating activity for a series of quinazoline-2,4(1H,3H)-diones and quinazoline-4(3H)-one guanidine derivatives. In the present work, novel N1,N3-bis-substituted quinazoline-2,4(1H,3H)-dione derivatives bearing two guanidine moieties were synthesized and pharmacologically profiled. The most potent NHE-1 inhibitor 3a also possesses antiplatelet and intraocular-pressure-reducing activity. Compound 4a inhibits NO synthesis and IL-6 secretion in murine macrophages without immunotoxicity and alleviates neutrophil infiltration, edema, and tissue lesions in a model of LPS-induced acute lung injury. Hence, we considered quinazoline derivative 4a as a potential agent for suppression of cytokine-mediated inflammatory response and acute lung injury.

Keywords: LPS; NHE-1; cytokine release; lung injury; macrophage; quinazoline-2,4(1H,3H)-dione.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of the data; in the writing of the manuscript; nor in the decision to publish the results.

Figures

Figure 1
Figure 1
Putative role of NHE-1 in inflammation.
Figure 2
Figure 2
Synthesis of the target compounds: (i) BrCH2C(O)OBn, K2CO3, DMF, 25 °C, 24 h, 62–65%; (ii) NH2C(NH)NH2 · HCl, KOH, 95% EtOH, reflux, 10 min, 68–81%; (iii) NH2C(NH)NHNH2 ·12H2CO3, KOH, 95% EtOH, reflux, 1 h, 60–63%.
Figure 3
Figure 3
Compound 4a has minimal impact on phagocytic activity and viability of C57bl/6j peritoneal macrophages. Data as the mean and 95% C.I. (n = 100). Statistical significance: ** p < 0.01, *** p < 0.001, **** p < 0.0001 vs. DMSO; #### p < 0.0001 vs. intact cells (1-way ANOVA, Dunnet’s post-test).
Figure 4
Figure 4
Compound 4a alleviated sickness behavior in the C57bl/6j murine model of LPS-induced acute lung injury. Data as the mean and SD, n = 5.
Figure 5
Figure 5
Compound 4a limits IL-6 secretion in the C57bl/6j murine model of LPS-induced acute lung injury. Data as the mean and SD, n = 5. Statistical significance vs. LPS (1-way ANOVA, Dunnet’s post-test): ** p < 0.01.
Figure 6
Figure 6
Compound 4a preserves normal permeability of alveolar vessels in the C57bl/6j murine model of LPS-induced acute lung injury. Data as the mean and SD, n = 5.
Figure 7
Figure 7
Compound 4a prevents leukocyte infiltration and lymphocyte recruitment in the C57bl/6j murine model of LPS-induced acute lung injury. Data as the mean and SD, n = 5. Statistical significance (1-way ANOVA, Dunnet’s post-test): * p < 0.05 vs. Vehicle + LPS (1-way ANOVA, Dunnet’s post-test); ** p < 0.01 vs. LPS; # p < 0.05 vs. Vehicle.
Figure 8
Figure 8
Sections of lung tissue, hematoxylin and eosin staining, ×400 total magnification: (a) vehicle; (b) LPS + vehicle; (c) LPS + dexamethasone; (d) LPS + 4a.
Figure 9
Figure 9
Sections of lung tissue, CD68+ immunostaining, nuclei stained with Mayer’s hematoxylin, ×400 total magnification: (a) vehicle; (b) LPS + vehicle; (c) LPS + dexamethasone; (d) LPS + 4a.

References

    1. De Vito P. The sodium/hydrogen exchanger: A possible mediator of immunity. Cell. Immunol. 2006;240:69–85. doi: 10.1016/j.cellimm.2006.07.001. - DOI - PubMed
    1. Shi Y., Kim D., Caldwell M., Sun D. The role of Na(+)/H (+) exchanger isoform 1 in inflammatory responses: Maintaining H(+) homeostasis of immune cells. Adv. Exp. Med. Biol. 2013;961:411–418. doi: 10.1007/978-1-4614-4756-6_35. - DOI - PubMed
    1. Haddad J.J., Land S.C. Amiloride Blockades Lipopolysaccharide-Induced Proinflammatory Cytokine Biosynthesis in an I κ B-α/NF-κ B–Dependent Mechanism: Evidence for the Amplification of an Antiinflammatory Pathway in the Alveolar Epithelium. Am. J. Respir. Cell Mol. Biol. 2002;26:114–126. doi: 10.1165/ajrcmb.26.1.4657. - DOI - PubMed
    1. Haddad J.J. Amiloride and the regulation of NF-κB: An unsung crosstalk and missing link between fluid dynamics and oxidative stress-related inflammation—Controversy or pseudo-controversy? Biochem. Biophys. Res. Commun. 2005;327:373–381. doi: 10.1016/j.bbrc.2004.11.166. - DOI - PubMed
    1. Adapted from “NF-KB Signaling Pathway”, by BioRender.com. 2022. [(accessed on 3 October 2022)]. Available online: https://app.biorender.com/biorender-templates.

LinkOut - more resources